Iterum Therapeutics plc
ITRM
$1.10
$0.021.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.49% | -2.89% | 2.31% | 4.19% | -19.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -67.89% | -70.71% | -63.26% | -27.75% | 44.22% |
| Operating Income | 67.89% | 70.71% | 63.26% | 27.75% | -44.22% |
| Income Before Tax | 46.34% | -60.33% | 58.81% | 27.78% | -144.94% |
| Income Tax Expenses | -82.39% | -15.53% | -83.42% | -60.98% | 40.59% |
| Earnings from Continuing Operations | 46.76% | -57.18% | 59.18% | 28.19% | -142.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.76% | -57.18% | 59.18% | 28.19% | -142.87% |
| EBIT | 67.89% | 70.71% | 63.26% | 27.75% | -44.22% |
| EBITDA | 68.98% | 69.97% | 61.79% | 23.94% | -46.80% |
| EPS Basic | 73.71% | -2.25% | 68.08% | 41.00% | -126.55% |
| Normalized Basic EPS | 73.49% | -4.32% | 67.79% | 40.66% | -128.51% |
| EPS Diluted | 73.52% | -2.25% | 68.08% | 41.00% | -126.55% |
| Normalized Diluted EPS | 73.49% | -4.32% | 67.79% | 40.66% | -128.51% |
| Average Basic Shares Outstanding | 102.48% | 53.72% | 27.89% | 21.69% | 7.20% |
| Average Diluted Shares Outstanding | 102.48% | 53.72% | 27.89% | 21.69% | 7.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |